Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for stomach cancer: drug combo aims to outperform chemo

NCT ID NCT07362186

Recruiting now Disease control Sponsor: LaNova Medicines Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new combination of drugs (LM-108 and toripalimab) against standard chemotherapy for people with advanced stomach cancer that has gotten worse after first treatment. About 400 adults with a specific marker (CCR8-positive) will be randomly assigned to receive either the new combo or chemo. The goal is to see if the new combo helps people live longer and slows cancer growth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED OR METASTATIC GC AND GCJ ADENOCARCINOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Cancer Hospital

    RECRUITING

    Beijing, Beijing Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.